Last updated: July 16, 2026
Pfizer Inc. v. Breckenridge Pharmaceutical Inc. (1:17-cv-01532) Litigation Summary and Patent Infringement Analysis
Executive summary: The U.S. District Court litigation Pfizer Inc. v. Breckenridge Pharmaceuticals Inc. (Case No. 1:17-cv-01532) is a Hatch-Waxman patent-infringement action tied to an Abbreviated New Drug Application (ANDA). The procedural posture and merits in such cases turn on which Orange Book patents Pfizer asserted, what Breckenridge filed in its ANDA notice (typically Paragraph IV certifications), and what defenses or claim constructions the court adopted.
However, the case-specific record (asserted patent numbers, formulation/method-of-use/method-of-manufacture claims, court rulings, dates, settlement terms, and final dispositions) is not included in the information provided. Without that docket-level and merits-level data, a complete and accurate litigation summary cannot be produced.
What patents were asserted in Pfizer v. Breckenridge 1:17-cv-01532?
A reliable litigation summary requires the exact Orange Book patents asserted by Pfizer in this case, including:
- Patent numbers and titles (e.g., composition, formulation, method-of-use, manufacturing method).
- Which claims were asserted (independent vs dependent claim numbers).
- The asserted theory of infringement (literal infringement, doctrine of equivalents, inducement, etc.).
- The ANDA carve-out details if any were part of the notice.
Without the asserted patent list and claim set from the case filings, the patent-protection analysis cannot be specific enough to be actionable.
What Orange Book patents did Pfizer list for the asserted drug?
In Hatch-Waxman actions, the asserted patents typically come from:
- Active ingredient + composition of matter patents
- Formulation patents (e.g., particular drug-release profiles, excipient systems, tablet/suspension compositions)
- Method-of-use patents (dosage regimens, patient populations, biomarkers)
- Less commonly for direct infringement: manufacturing process patents
The litigation analysis depends on matching Pfizer’s asserted patents to the Orange Book listing tied to the ANDA.
When did the Pfizer v. Breckenridge 1:17-cv-01532 case reach key milestones?
A milestone timeline should include, at minimum:
- Complaint filing date and asserted patent inventory
- Service and answer deadlines
- Claim construction order and date(s)
- Summary judgment or dispositive motion outcomes
- Trial date(s) or whether it resolved on motions
- Final judgment date and any permanent injunction scope
- Post-judgment developments (appeal, stay, license agreement implementation, final settlement terms)
This requires docket events and court orders from the case record. The current input does not supply those.
Did the court enter an injunction, or was the case stayed/settled?
Hatch-Waxman cases frequently end via:
- Consent judgment after settlement
- Dismissal without prejudice
- Denial of injunction with damages proceedings (less common)
- Final judgment on noninfringement/invalidity
- Entry of injunction tied to specific patents and carve-outs
In this matter, the applicable disposition is not provided.
How did Breckenridge challenge Pfizer’s asserted patents in 1:17-cv-01532?
Defense frameworks in ANDA patent infringement cases typically include:
- Noninfringement (ANDA product does not meet claim limitations)
- Invalidity (anticipation/obviousness under 35 USC 102/103, written description/enablement under 112, indefiniteness under 112(b))
- Statutory defenses tied to 35 USC 271(e)(2)
- Design-around arguments, including excipient or release-profile differences for formulation patents
But a defensible analysis requires the actual invalidity theories and claim construction positions used in filings or rulings.
What claim construction issues drove the outcome?
For litigation of this type, outcomes often hinge on:
- Terms defining particle size, polymorph, solvate/hydrate, crystallinity
- Release specifications (IR, XR, ER kinetics)
- Method steps in method-of-use claims (timing, dosing, patient selection)
- Process limitations (temperature ranges, mixing order, drying steps)
These issues must be drawn from claim construction orders or trial findings, which are not included.
What did the court decide on infringement in Pfizer v. Breckenridge?
A summary should report:
- Which asserted patents survived dispositive motions
- Whether the court found:
- Infringement as to any claim(s)
- Noninfringement as to all asserted claims
- Pending/abandoned claims
- The practical consequences for ANDA launch timing
The case’s rulings are not available in the provided material.
What did the court decide on validity in Pfizer v. Breckenridge?
Validity analysis should quantify:
- Patents held invalid in whole/part
- Key prior art references (with publication numbers)
- Obviousness rationales and claim-element mapping
- Whether invalidity was decided via summary judgment or post-trial
No validity findings are provided.
What settlement or license terms affected generic launch risk?
Where settlements occur, business impact depends on:
- Effective settlement date
- Payment type (if publicly disclosed), including “no-AG” structure if applicable
- Authorized launch dates or “at-risk” triggers
- Geographic scope (US-only vs broader settlements)
- Carve-outs for pediatric exclusivity, specific strengths, or formulations
- Whether the settlement included license to patents (and under what royalties/territory)
Without settlement documentation from the docket, the launch-risk analysis cannot be accurately stated.
How does FDA regulatory status intersect with this litigation (ANDA/Paragraph IV)?
In Hatch-Waxman:
- Breckenridge’s ANDA submission date and Paragraph IV certification date(s) govern 30-month stay eligibility.
- Court decision timing can shorten or extend the stay.
- Post-decision, the FDA may approve contingent on non-infringement findings or settlement.
A full analysis requires:
- Which product(s) Breckenridge sought to market
- ANDA number(s)
- Strength and dosage form(s)
- Certification paragraph detail for each asserted patent
- Whether any changes were made (amendments/corrections) during litigation
No FDA/ANDA identifiers are provided.
What is the Orange Book status for the product at issue in 1:17-cv-01532?
An Orange Book-driven analysis includes:
- The list of Orange Book patents tied to the reference listed drug (RLD)
- Patent expiration dates
- Whether patents are:
- “Listed patents” tied to the RLD
- “Delisted” due to expiration or disclaimer
- Any pediatric exclusivity period
The Orange Book listing and expiration schedule must be tied to the exact drug product in this case, which is not specified.
Which companies are competing with Breckenridge on the same ANDA pathway?
Business analysis typically maps:
- Other ANDA filers targeting the same RLD and strengths
- The status of other Paragraph IV litigations
- Potential design-around strategies by peers
This requires the identity of the RLD and ANDA landscape, absent from the provided input.
How strong is Pfizer’s patent estate for this drug versus Breckenridge’s generic product risks?
A strength assessment requires:
- Number of asserted patents
- Their types (composition vs formulation vs method-of-use)
- Expected enforceability based on:
- claim scope
- typical prior art patterns for that drug family
- litigation history in courts
- Whether the estate is consolidated in a single family or spread across unrelated families
Without the asserted patent numbers and outcomes, strength cannot be measured.
What generic entry risks exist after the court’s resolution in 1:17-cv-01532?
Generic entry risk after litigation depends on:
- Whether any patents were found invalid or not infringed
- Whether injunctions remained in place
- Whether a settlement granted a “licensed launch”
- Whether appeals stayed enforcement
A post-resolution launch-risk conclusion requires the final disposition, which is not provided.
Key Takeaways
- A complete litigation summary for Pfizer Inc. v. Breckenridge Pharmaceutical Inc. (1:17-cv-01532) requires docket-specific facts: asserted patent numbers, ANDA/Paragraph IV details, claim construction and merits decisions, and any settlement or injunction terms.
- Those case record elements are not present in the provided information, so a complete and accurate analysis cannot be produced from the current input.
FAQs
What is 1:17-cv-01532 (Pfizer v. Breckenridge) about in general terms?
It is a Hatch-Waxman patent infringement case connected to an ANDA and Orange Book patents, but the exact drug, asserted patents, and court determinations are not provided.
Does a Paragraph IV certification apply automatically in this type of case?
In Hatch-Waxman framework, it is typical; however, the specific certifications made by Breckenridge for the asserted patents are not included.
Which court orders matter most for Hatch-Waxman infringement outcomes?
Claim construction and dispositive validity/infringement orders usually drive outcomes, but the orders in this case are not supplied.
How do settlements usually change generic launch timing?
Settlements often define launch dates and patent carve-outs, but any settlement terms for this case are not given.
How do appeals affect FDA approval and entry after litigation?
Appeals can lead to stays and delayed enforcement, but this case’s appellate posture is not provided.
References
No sources were cited because the case record (docket entries/orders, asserted patent list, or FDA/Orange Book linkage) was not provided.
